China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced plans to enter into a technology transfer agreement with compatriot firm Fujian Ruitailai Pharmaceutical Technology Co., Ltd. Under the agreement, Cosunter will obtain all technologies, materials, and rights to Ruitailai’s ursodeoxycholic acid capsules (250mg) for RMB 13.5 million (USD 1.9 million). This acquisition aims to expand Cosunter’s portfolio in the hepatobiliary disease treatment market.
Ursodeoxycholic Acid: Drug Profile and Market Potential
Ursodeoxycholic acid (UDCA), chemically named 3α,7β-Dihydroxy-5β-Cholestan-24-oic acid, is a hydrophilic, non-cytotoxic bile acid. Leveraging its cholagogic, cytoprotective, anti-apoptotic, antioxidant, and immunomodulatory effects, UDCA has been widely used in the treatment of various clinical hepatobiliary diseases. The drug is approved globally for the treatment of cholesterol gallstones, cholestatic liver disease, and bile reflux. In the US, it is the only drug approved for the treatment of cholestatic liver diseases, highlighting its significant market potential.
Future Outlook
The technology transfer agreement underscores Cosunter’s strategic focus on expanding its presence in the hepatobiliary disease treatment market. By acquiring the rights to UDCA capsules, Cosunter aims to enhance its product offerings and address significant unmet medical needs in this therapeutic area.-Fineline Info & Tech
